Benefits of Surgical Treatment of Stage IV Breast Cancer for Patients With Known Hormone Receptor and HER2 Status
- 30 October 2020
- journal article
- research article
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 28 (5) , 2646-2658
Abstract
For the 6% of breast cancer patients with a diagnosis of stage IV disease, systemic therapy is the cornerstone of treatment, with an unclear role for surgeKeywords
This publication has 29 references indexed in Scilit:
- Locoregional surgical treatment improves the prognosis in primary metastatic breast cancer patients with a single distant metastasis except for brain metastasisThe Breast, 2019
- Impact of Breast Surgery in Primary Metastasized Breast CancerAnnals of Surgery, 2019
- Primary tumor resection in stage IV breast cancer: A systematic review and meta-analysisEuropean Journal of Surgical Oncology, 2018
- Surgical treatment of the primary tumour improves the overall survival in patients with metastatic breast cancer: A systematic review and meta-analysisMolecular and Clinical Oncology, 2016
- Locoregional treatment versus no treatment of the primary tumour in metastatic breast cancer: an open-label randomised controlled trialThe Lancet Oncology, 2015
- Meta-Analysis to Determine if Surgical Resection of the Primary Tumour in the Setting of Stage IV Breast Cancer Impacts on SurvivalAnnals of Surgical Oncology, 2013
- Surgery of primary tumors in stage IV breast cancer: an updated meta-analysis of published studies with meta-regressionMedical Oncology, 2012
- Third consensus on medical treatment of metastatic breast cancerAnnals of Oncology, 2009
- The impact of new chemotherapeutic and hormone agents on survival in a population‐based cohort of women with metastatic breast cancerCancer, 2007
- Does aggressive local therapy improve survival in metastatic breast cancer?Surgery, 2002